Enhancing Patient Access to Therapies for Inflammatory Bowel Disease (IBD)
An estimated 1.6 million Americans suffer from Inflammatory Bowel Disease (IBD), an umbrella term for two distinct conditions – Crohn’s disease and ulcerative colitis – both characterized by chronic inflammation of the gastrointestinal tract. IBD can significantly affect a patient’s quality of life and may impose tremendous public health burdens, including economic costs. There is currently no cure for IBD, and patients require chronic, long-term treatment. Major scientific advances within the fields of genetics, immunology, and microbiology have led to a greater understanding of the underlying mechanisms involved in IBD and an increase in the number of treatment options available for IBD patients. In recognition of Crohn’s and Colitis Awareness Week, we are pleased to convene this informal discussion as an opportunity to provide more information about what it’s like for patients battling these conditions, issues clinicians face in treating these patients, and how Congress can help improve access to necessary treatments.
With remarks from:
Rep. Brad Wenstrup, M.D. (R-OH) – invited
Rep. Raul Ruiz, M.D. (D-CA) – invited
Rep. Ryan Costello (R-PA) – invited
This briefing will feature presentations from expert clinicians, patient advocates, and biomedical innovators, including:
- Uthra Sundaram, SVP, Specialty Business Unit, Takeda Pharmaceuticals U.S.A., Inc.
- Michael Weinstein, M.D., American Gastroenterological Society and Digestive Health Physicians Association
- Laura Wingate, SVP, Education, Support, & Advocacy, Crohn’s & Colitis Foundation
- Kate Detwiler, an IBD Patient
- Jennifer Nieto Carey, VP, Federal Government Relations & Alliance Development, California Life Sciences Association (CLSA) – Moderator
Inflammatory Bowel Disease (IBD) Briefing
Wednesday, December 6, 2017
1310 Longworth House Office Building
RSVP to Danielle Mitchell (email@example.com or 202-743-7561)
This event has been designed to comply with House and Senate Ethics rules for widely attended events under House Rule 25, clause 5(a)(4)(A) and Senate Rule 35.1(d)(1). Members and staff who have questions should contact their respective Ethics Committee. Food and refreshments are provided solely by the California Life Sciences Association.
* This event is supported in part through a sponsorship from Takeda Pharmaceuticals America*